Patients with ADCLS report symptoms similar to those reported by patients with chronic fatigue syndrome (CFS). This registry could serve as the vehicle to perform the prospective trials that are needed to generate potential evidence to support the use of HBOT on Lyme disease.Ī subset of patients reporting a diagnosis of Lyme disease can be described as having alternatively diagnosed chronic Lyme syndrome (ADCLS), in which diagnosis is based on laboratory results from a nonreference Lyme specialty laboratory using in-house criteria. An HBOT registry for Lyme disease and CLD would be an important tool to better understand the number of patients treated and whether or not HBOT has a beneficial effect on this puzzling and controversial condition. Neither Lyme disease nor CLD is an approved indication for HBOT, and evidence is scarce to support the use of HBOT on this confusing disease, although some dramatic cases of improvement have been reported. The protean nature of Lyme disease in its presentation and response to conventional therapy has challenged research and driven patients, especially those with CLD, to seek alternative therapies, including hyperbaric oxygen therapy (HBOT). burgdorferi infection, a diagnosis that is not promoted by the general medical and scientific community. Patient groups advocate for chronic Lyme disease (CLD), a condition of persistent symptoms in patients which may or may not be related to B.
Persistent symptoms and reinfection may occur after antibiotic therapy. Antibiotics administered early on in the disease cure up to 90 % of infected persons. Less than optimal laboratory testing is an unreliable diagnostic option for up to 20 % who present without objective symptoms. The hallmark manifestation of Lyme disease, an erythema migrans around the tick bite, is found on most infected persons. Lyme disease, a bacterial infection caused by Borrelia burgdorferi and transmitted to humans by the bite of infected blacklegged ticks, is the most common vector-borne disease in the United States.
0 kommentar(er)
